1. Gastrointestinal Tract
Lymphoma
Dr. Shad Salim Akhtar
MBBS, MD, MRCP(UK), FRCP(Edin), FACP(USA),
Member AUICC Fellows
Consultant Medical Oncologist
Medical Director
Prince Faisal Oncology Center & KFSH
Prof. of Clinical Medicine, Qassim Medical University
Buraidah, Al-Qassim, KSA
2. Non Hodgkin's Lymphoma
Heterogeneous collection of lympho-proliferative
diseases
Is it the same disease at all sites???
Major divisions
Nodal
Extra nodal
Around 33-40% are extra nodal
GIT is the commonest extra- nodal site
Around 50%
Henessey BT et al. Lancet Oncol 2004;5:341
3. Extra nodal NHL
Clinically dominant (>75%) extra nodal
component with
No or Minor nodal involvement (25%)
Tonsils / Waldeyer’s ring??
Zucca E et al: Ann Oncol 1997; 8:727
4. GI NHL-Definition
Localized disease to the GIT
Stage IE, IIE disease
Lymphoma patients exhibiting GI symptoms
or have a predominant lesion in GI
Dawson IMP et al: Br. J Surg 1961; 49:80
Lewin KJ et al: Cancer 1978; 42:693
Haber DA et al: Semin Oncol 1988; 15:154
5. All patients who present with
NHL that apparently originated
at an extra nodal site even in
the presence of disseminated
disease, as long as the extra
nodal component is dominant”
GI NHL-Definition
Krol ADG et al: Ann Oncol 2003; 14:131
6. NHL-Increasing incidence
1970 10.2/100,000
1990 18.5/100,000
81% increase or 3.6% per year
Extra nodal NHL 3-6.9%/year
Nodal NHL 1.7-2.5%/year
Vose JM et al: Hematology 2002; 242
Ries LAG et al: National Cancer Institute 2002`
7. GI NHL-Sites of involvement
Author Total Gastric Intest
Koch P 371 277 70
Liang R 442 238 184
Radaszkiewicz T 307 264 59
Morton JE 175 78 95
Azab MB 106 55 43
Amer MH 185 94 91
El Foudeh M 215 185 66
Nakamura S 455 342 96
Ducreux M 78 42 13
9. GI NHL-Symptoms versus site
Stomach Small
intestine
Colorectal
Pain Pain Pain
Nausea &
Vomiting
Obstruction Bleeding
Weight loss Weight loss Diarrhea
Bleeding Malabsorption
Crump M et al: Semin Oncol 1999; 26:324
10. GI NHL-Staging system TNM
I Single nodal region
Localized single extra lymphatic organ/site IE
II 2 or more node regions same side of diaphragm
Localized single extra lymphatic organ/site with
its regional nodes+/- other nodes on the same
side of diaphragm
IIE
III Node regions both sides of diaphragm+/-
localized single extra lymphatic organ/site
Spleen / Both
IIIE
IIIS
IIIES
IV Diffuse or multi focal involvement of extra
lymphatic organs+/- regional nodes; isolated
extra lymphatic organ and non regional lymph
nodes
Sobin LH et al: TNM Manual 6th Edition 2002; 238
11. GI NHL-Staging system
Stage I
Tumor confined to the GI tract
Single primary site or multiple non contiguous
lesions
Stage II
Tumor extending into abdomen from a primary
GI site
Nodal involvement
II1 local (paragastric / paraintestinal)
II2 distant (mesenteric, para-aortic, paracaval, pelvic,
inguinal)
Rohatiner A et al: Ann Oncol 1994; 5:397
12. Stage IIE
Penetration of serosa to involve adjacent
organs or tissues
Stage IV
Disseminated extra nodal involvement or
GIT lesion with supradiaphragmatic nodal
involvement
GI NHL-Staging system
Rohatiner A et al: Ann Oncol 1994; 5:397
13. ? X to denote the organ of origin
X [stomach] II (gastric NHL with local nodes
involved)
X [stomach, colon] II
Addition of IP index as in AJCC Cancer
Staging Manual 6th
Edition?
GI NHL- Staging
Suggested modifications
Armitage JO; N Engl J Med 2005; 352:1250
Grothus-Pinke B et al: Ann Oncol 1996; 7:S126
14. GI NHL-Work up
History & physical examination
Weight loss not recorded as a B symptom
Waldeyer’s ring assessment especially with
limited GI involvement
Routine bloods
Endoscopic examination
CT
Barium studies
Bone marrow examination!!!
Endoscopic USG
15. GI NHL-Do they need
laparotomy for diagnosis?
In 30-50% of intestinal NHL who may
present as an emergency
Endoscopic biopsy from accessible
lesions
Diagnostic accuracy 62% to 98.5%
First attempt diagnosis 80% of above
May miss areas of transformation
Al Akwaa AM et al: Worl J Gastroenterol 2004; 10:5
16. FNAC
Laparoscopic biopsy
Frozen section facility
Bone marrow in the same sitting
All tissues must be sent for
Histological
Immunohistochemistry
Cytogenetic studies
GI NHL-Diagnosis?
Kaleem Z et al: Am J Clin Pathol 2001; 115:136
Koniaris LG et al: J Am Coll Surg 2003; 197:127
17.
18.
19. GI NHL-Histological types
Diffuse B cell large cell
Secondary DLBCL
Extra nodal marginal zone lymphoma (MALT)
Follicular lymphoma
Mantle cell lymphoma
Burkitt’s lymphoma
Enteropathy type T cell lymphoma
Peripheral T cell lymphoma NOS
Majority of cases seen in KSA are DLBCL type
22. OS and EFS of
nodal vs extra
nodal lymphoma
in 1168 patients
including 216 GI
lymphomas
defined as per
Krol ADG et al.
Krol ADG et al: Ann Oncol 2003; 14:131
26. Gastrectomy – Points in favor
Multiple studies
Stage I surgical resection may be curative
? The number of MALT lymphomas in these series
Patients undergoing radical excision have a
superior outcome
? Inidicator of low burden disease
Multimodality treatment better survival
Small non randomized retrospective studies
Data collected is of many years
Crump M et al: Semin Oncol 1999; 26:324
27. Role of radiotherapy
Multiple retrospective studies positive for
multimodality therapy
Has been used as the sole modality of
therapy especially in MALT
Post operative adjuvant 88% OS rate
Problems of late toxicity
Reserve for residual disease, elderly or
inoperable patients
Koniaris LG et al: J Am Coll Surg 2003; 197:127
28. Adjuvant RT in Early Stage NHL
Miller TP et al NEJM 1998;339:21
Comp surg excision
Complete response
5 yrs surv RFS
5 yrs surv OS
Life threat toxic
58
104/243(73%)
64%
72%
40%
58
106/142(75%)
77%
82%
30%
0.03
0.02
0.06
CHOP 8 CHOP3+RT
Stage I/II lymphoblastic NHL excluded
29. What therapy?
Stage IPI Rx 5yr
MSur
Limited
stage
Proposed
description
I, IE 0 CHOP(3)
+ RT
>90% Yes Very
limited
I, IE,
II, IIE
(non
bulky)
>=1 CHOP(3)
+ RT
70% Yes Limited
Bulky
II, IIE
>=1 CHOP(8) 50% No Advanced
Fisher RI et al: Hematology 2004; 221
30. German multi-center study
Prospective non randomized
Surgery left to the treating physician
Post operative therapy standardized
31. 277 patients accrued and 185 analyzed
IE 96; II1E 58; II2 E 31
High grade 101 pts (54.6%)
70% without low grade component
Type Stage CT RT
HG IE CHOP 4 EFRT (30G) +
boost
IIE COP 6 IFRT (40G)
Gastric Lymphoma Therapy-
German MC Study
Koch P et al: J Clin Oncol 2001; 19:3874
32. Gastric Lymphoma Therapy-
German MC Study
Type Stage CT RT
LG resected IE X EFRT
IIE COP 6 EFRT
LG unresec IE EFRT+boost
IIE COP 6 EFRT+boost
Koch P et al: J Clin Oncol 2001; 19:3874
33. Gastric Lymphoma Therapy-
German MC Study
High grade No surgery Surgery+CRT
Number 54 47
EFS 69.6% 76.6% NS
OS 77.9% 78.9% NS
Low grade
Number 52 32
EFS 87.6% 82.2% NS
OS 90.2 87.2 NS
Koch P et al: J Clin Oncol 2001; 19:3874
36. EFS
EFS of gastric lymphoma resected completely vs
partial or incomplete resection
Koch P et al: J Clin Oncol 2001; 19:3874
37. Gastrectomy present status
Organ preservation is an important quality of
life issue
Resectabilty rates range from 60-80%
Operative mortality and morbidity rates range
from 3-25%
Patient preference, tumor size, stage and
resectability should be considered
40. Binds CD20, which is present on normal and malignant pre-
B and mature B cells;
>90% of B-cell NHL express CD20
May induce antibody-dependent cell-mediated cytotoxicity
(ADCC) and complement-dependent cytotoxicity, based on
in vitro data
Also triggers apoptosis (programmed cell death) in vitro
No apparent dependence on cell cycle for activity
Rituximab
41. DLBCL Gastric origin
Algorithm for therapy
Localized (stage I, II)
Advanced disease
Complications
Complete resectionPossible
Not possible
CHOP X 6-8 +Ritux
CHOPX3+Ritux
IFRT (avoid in young)
Residual disease
EFRT (avoid in young)
Resection
CR
42. GI NHL-Site of disease-
Geographical Variation
Site USA Ger Fra KSA NGui Nigeria Jord
Gast 77 277 43 185 24 19 23
Small
Intest
36 35 39 66* 55 62 59
Ileo-
cecal
26 13
Colon 17 3 10 21 19 15
Rect 6 6
Panc 10 5 0 0
Diffu 5 24 16 10 0 2
Kniaris LG :J Am Coll Surg2003;197:127 Koch P :JCO 2001;19:3861
43. Intestinal DLBCL
Surgical intervention is less controversial
Acute presentation more common
Completely resected patients do better
Generally poorer prognosis as compared to
gastric
Survival
Early stage disease better
Surgery+CT+RT 50-70%
Single modality 30-50%
Koniaris LG et al: J Am Coll Surg 2003; 197:127
Daum S et al: J Clin Oncol 2003; 21:2740
44. Marginal Zone
Mantle Zone
Germinal Centre
(Contains post germinal centre B cells, monocytoid
B cells, plasma cells and centrocyte like cells)
Normal MALT
Rooney N et al: Curr Diag Pathol 2004; 10:69
45. Calam J etal. BMJ 2001;323:980
Relation of H pylori infection to UGI conditions
46. H pylori and Malt lymphoma
~90% have H pylori in gastric mucosa~90% have H pylori in gastric mucosa
Case control studies confirm relationshipCase control studies confirm relationship
between previous infection and lymphomabetween previous infection and lymphoma
Clonal B cell detection in chronic gastritisClonal B cell detection in chronic gastritis
which precedes lymphomawhich precedes lymphoma
H pylori strain specific T cells promoteH pylori strain specific T cells promote
lymphoma growth in culturelymphoma growth in culture
Eradication of H pylori causes regression inEradication of H pylori causes regression in
75% of caces75% of caces
47. Gastric MALT lymphoma
MALT reacts with the antigen
present within the lumen
An Pr Cells +H pyhlori
antigen+CD4+ T cells
stimulate peoliferation of B
cells
B cells synthesize
immunoglobulins
Immunoglobulins react with
autoantigens
Parsonnet J et al: N Engl J Med 2004; 350:213
50. Gastric MALT types
A low grade classical
<5% blasts and clusters of <10 cells
B
10-20% transformed cells
Clusters of >20 cells
C high grade transformation with sheets
of transformed cells
D no MALT component is recognizable
Isaacson PG: Hematology 2001; 241
51. MALT lymphoma management
Careful imaging
CT scan
Endoscopic ultrasonography
Sufficient tissue to
Differentiate from
Mantle cell lymphoma
Follicular lymphoma
Confirm presence of more transformed clone
Immunohistochemical studies (bcl2 expression)
52. Gastric MALT management
Antibiotic therapy
Regression in approximately 75% cases
Time to regression may be as long as 18 months
Predictors of failure of antibiotic therapy
t(14:18) do not respond to antibiotics
Node positive disease
Depth of invasion muscularis mucosa
Lymphoma clone persists
Therefore it becomes dormant rather than disappear
Isaacson PG; Best Prac & Res 2005; 18:57
Cavalli F et al: Hematology 2001; 241
53. Surgical resection
Antrectomy usually adequate
Radiotherapy
Chemotherapy
Alone or in combinations
5 yr DFS
>95% in IE
75% in IIE
Gastric MALT management
antibiotic failure or advanced
Koniaris LG: J Am Coll Surg 2003; 197:127
54. IPSID
MALT type B cell lymphoma
Proximal small intestine involved
Geographical distribution
Mediterranean Middle East
Africa
Far East
Children & young adults
Monotypic truncated immunoglobulin α heavy
chain
Lecuit M et al: N Engl J Med 2004; 350:239
55. IPSID
Campylobacter jejuni
Small group of patients (4/6)
FISH, PCR, DNA sequencing and
immunohistochemistry
Early stages respond to antibiotics
Non responsive pts progress to lymphoma
Lymphoplasmacytic & immunoblastic
Locally invasive and metastatic
Poor prognosis
Hinweis der Redaktion
Unlike HD NHL is a group of more hetergenous collection of lymphoproliferative malignancies. With the passage of time we have come to recognize probably geneticall y different NHLs with different causes and prognosis. In spite of a similar HP picture the DBCL presenting in different areas is identified as a different subtype, like Pr. Med lymph, Pr. Eff lymphoma. In fact the question which is being asked is if Squamous cell carcinoma arising in different areas is treated as a different disease, why should NHL at any site be the same disease. Notwithstanding the major differences, traditionally, NHL has been classified as nodal and extra-nodal, the relative frequency of extra-nodal NHl varies in different series. Genreally around 33-40% are extranodal lymphomas. What is an extranodal lymphoma.
Different criteria have been proposed. Generally a lymph can b considered extra nodal if after routine staging investigations there is either no or minor nodal component of the disease. A minor nodal component has been described as &lt;25% of the tumour and a major extra nodal component means if the latter constitutes &gt;75% of the NHL. However, this is not a widely accepted cut off proportion.
Variously defined but the definition of Lewin is generally more acceptable. Dawson’s criteria were very stringent including only those patients who had GI lymphoma with normal CXray, no hepatosplenomegaly, no superficial or mediastinal lymphadenopathy, normal white cell count and predominant tumor mass in the bowel only with local lymphadenopathy.
In a retrospective analysis looking at various definitions of extra nodal lymphoma, Krol an his collaegues from Netherland analysed 389 patients to compare the survival according to various definitions. Their conclusion was as above:
Interesting observations of NHL incidence need to be stressed. The incidence of NHL has been increasing in USA at the above rate and the increase has been more so in the extra-nodal NHL. The increase has leveled off since 1990’s except among the black american females.
The frequency of particular organ involvement varies in different geographical regions stomach being the commonest site of involvement in the west and the gulf region whileas intestinal involvement is more common in mediter middle east, africa and far east.
The most commonly used staging system is the Ann Arbor classification with the Muschoff modification. The TNM manual incorporates the same staging system. In this system the suffix E denotes both invading growth as well as extra nodal origin, at the same time stage IV NHL originating at multiple sites cannot be compared with nodal lymphoma involving multiple non nodal or non GI organs. Hence this system needs further modification.
In view of marked variation in reporting an International Workshop held in Lugano suggested the above staging system for GI NHL.
Here E suffix is restricted to indicate invading growth
It has been therefore suggested to use the Ann Arbor classification with modifications as laid down in Lugano Conference restricting E for direct invasion and adding X for extra nodal origin. Additionally recently the significance of the IPI in determinig the prognosis of high grade NHL has been recognised by its inclusion in the staging system of the AJCC and it might be soon generalized.
Laparotomy is no longer needed in every patient, unless a patient presents with a surgical emergency diagnosis is established by endoscopic biopsy and the accuracy ranges from 62% in multi-institutional to 98% in single institutional studies.
A high index of suspicion must be maintained especially in semi elective cases and FNAC or a mucosal biopsy must be considered to avoid delay in therapy that would result from concerns about wound healing associated with laparotomy. If tissue has not been obtained before, an intra operative frozen section should be obtained to plan for further management like in small bowel tumors where 20% may be lymphomas.
Events in B cell development. The development and maturation process of B cells begins in the bone marrow. Here, the &quot;pre-B cell&quot; arises from the &quot;progenitor (Pro) B cell&quot; following rearrangement of the immunoglobulin heavy chain gene (symbolized with horizontal lines in black). Subsequently, rearrangement of the light chain genes occurs resulting in the expression of the whole immunoglobulin molecule on the cell surface, serving as an antigen receptor. With the production of this &quot;immature&quot; B cell, the initial phase of B-cell development is, thereby, completed. The &quot;immature&quot; B cell is so defined since it is unable to initiate an immune response following the presentation of a foreign antigen. The B-cell attains this ability only on leaving the bone marrow, passing through the blood stream and entering the peripheral lymphoid tissue. Here, the B cell migrates to the outer region of the lymph node in the &quot;primary&quot; follicles and, later, to the follicle mantles. This differentiation step is associated with the additional expression of IgD. These IgM+/IgD+ B cells are known as &quot;naive mature B-cells&quot;. When these cells come into contact with antigen (AG), which can bind to their immunoglobulin molecules, they transform into proliferating extrafollicular B blasts, from which short-lived plasma cells and &quot;antigen-induced&quot; or &quot;primed&quot; B cells are derived. These &quot;primed&quot; B cells initiate and maintain the germinal center reaction, during which they transform into rapidly proliferating centroblasts. During the mitotic proliferation and differentiation of the centroblasts into centrocytes, somatic mutations in the variable region of the immunoglobulin genes are inserted in a randomized manner (the mutations are represented by vertical lines). The centrocytes with advantageous mutations (i.e. those which lead to an increase in the affinity of the immunoglobulin receptor) differentiate further, passing out of the germinal centre into long-lived plasma cells or into &quot;memory&quot; B cells. The latter remain in the marginal zone. As a result of the differentiation phases of B-cells and of the somatic mutation process, 3 major different mature forms of B-cells can be identified:
• Naive mature B-cells (recirculating and sessile subtypes)
• Germinal center B-cells (centroblasts and centrocytes)
• Post germinal center B-cells which include memory B cells and long-lived plasma cells
From all of these different B-cell forms, malignant B-cell lymphomas arise, which distinguish themselves clinically and which are characterized in their biological behavior not only by the transformation event but also by the inherent characteristics of the cell of origin. Classical Hodgkin lymphomas, in which the phenotypical and clinical features are predominantly determined by the transformation event, are an exception to this rule.
FDC, folicular dendritic cell; , apoptosis
Figure 5. Model of B-cell non-Hodgkin&apos;s lymphoma (NHL) histogenesis and pathogenesis. A lymphoid follicle, constituted by the germinal center (GC) and the mantle zone (MZ), is represented together with the surrounding marginal zone (MargZ). Based on the absence or presence of IgV somatic mutations, B-cell NHL can be distinguished into two broad histogenetic categories: i) pre-GC derived NHL, lacking IgV mutations and including mantle cell lymphoma (MCL); ii) B-cell NHL derived from a cell that transited through the GC and harboring mutated IgV genes, exemplified in the figure by follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), MALT lymphoma, diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). In B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), the presence of somatically mutated IgV genes in &gt;50% of the cases also suggests a derivation from a GC experienced B cell. For each category, the arrow indicating the histogenetic origin is flanked by the genetic lesion most frequently associated with the lymphoma. In CLL/SLL, as well as in a subset of DLBCL, the relevant cancer related gene has not been identified.
Secondary diffuse large B cell meaning the one which has arisen on top of a MALT lymphoma
In a multivariate analysis however, the site of disease did not maintain its prognostic value. Instead other factors like IPI and bulky disease and b2 microglobin became important.
Bcl2 protein expression without t14:18 translocation respond better to immunotherapy.
As already discussed the diagnosis can now be made endoscopically. The rate of complications is rather low and routine surgery to prevent complications is no longer indicated.
Radiotherapy as an adjuvant as well as sole therapy has been found to be effective in treating GI lymphomas. However, as late toxicities are formidabel especially in younger patients who will be cured of their disease with multimodality therapy one should use radiotherapy only in special circumstances like in advanced disease after surgical resection, priamry therapy for older patients with small tumor burden or in patients with prohibitively high operative risk.
A number of studies have shown the effectiveness of RT in treating localized lymphomas.
Based on the updated SWOG data and that form Britic=sh Columbia Cancer Agency for limited disease NHL, we can conclude that the limited NHL actually can be further divided into various subgroups. While as CHOP3 +RT may be adequate therapy for a group as shown with an expected 5 yr surv &gt;90% others may need strategies as for advanced disease.
High-grade NHL. Conservative treatment was unaffected by
whether a resection had been performed or not. In stage IE, four
cycles of CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50
mg/m2, and vincristine 1.4 mg/m2 [maximum, 2 mg] each on day 1,
plus prednisone 100 mg on days 1 to 5)22 were followed by EF Rx
(30 Gy 10 Gy boost on tumor or residue). Patients in stage IIE
received six cycles of CHOP and additional involved-field Rx (40 Gy).
Low-grade lymphoma. After resection, patients in stages IE and
IIE were treated by extended-field radiotherapy (EF Rx) with total abdominal irradiation (30 Gy) and, in case of residual tumor, by an additional boost (10 Gy). Without resection, patients in stages IE and
IIE received EF Rx (30 Gy 10 Gy boost). In addition, in stage IIE,
six cycles of COP (cyclophosphamide 500 mg/m2 on days 1 to 5;
vincristine 1.4 mg/m2 [maximum, 2 mg] on day 1; prednisone 100
mg/m2 on days 1 to 5)21 preceded Rx for reduction of tumor load
Fig 7. CSS of both treatment groups in stages IE and IIE (nonrandomized comparison; all histologic subtypes).
EFS of gastric lymphoma resected completely vs partial or incomplete resection
The intestinal lymphoma is relatively uncommon and incidence varies according to geographic location. The IPSID areas being Mediterranean middle east, Africa and Far east.
Figure 1 Normal mucosa associated lymphoid tissue (MALT), top left haematoxylin and eosin, bottom left CD20
staining. The marginal zone contains post-germinal centre B-cells, including monocytoid B-cells, plasma cells and
centrocyte-like cells, which infiltrate the epithelium. Most plasma cells are found in the superficial lamina propria.
Relation of H pylori infection to upper gastrointestinal conditions.
Various factors affect the outcome of HP infection. These include the host response, the extent and the severity of gastric inflammation and hence the amount of acid secreted. It can elevate the acid secretion in people who develop duodenal ulcer, decrease acid through gastric atrophy in those who develop gastric ulcers or cancer and leave acid secretion unchanged in those who do not develop these diseases. H pylori also impairs the bioavailability of vitamin c in these patients who may already have a poor intake. Eradication of H pylori increases secretion of vitamin C into gastric juice which might increase protection against gastric cancer.
Marshall and Warren detected this organism in 1983. The spiral organisms between the junction of domes of the epithelial cells where it splits urea which leaks from the cell junction and ammonia is produced which increases the acidity.
Figure. The Pathogenesis of Gastric MALT Lymphoma (Panel A) and Immunoproliferative Small Intestinal Disease
(Panel B).
In gastric MALT lymphoma, CD4+ T cells that encounter
H. pylori
antigens displayed by antigen-presenting cells stimulate
the proliferation of neoplastic B cells. These B cells synthesize IgM, IgA, or IgG autoantibodies and differentiate to
varying degrees into mature plasma cells.
C. jejuni
may play the same part in immunoproliferative small intestinal disease
that
H. pylori
plays in gastric MALT lymphoma. However, in response to tissue autoantigens, the lymphoma cells
synthesize defective
a
heavy chains. The autoantigenic stimulus is consequently uncontrolled, and the result is a continuous
differentiation of lymphoma cells into atypical plasma cells. In both these conditions, the removal of the bacterial
T-cell stimulus inhibits the proliferation of lymphomatous B cells.
Figure 2 Early marginal zone lymphoma of MALT-type.
Proliferation of marginal zone cells with crypt infiltration.
Initially, proliferative drive is provided by HP
reactive T-cells. Removal of HP may control the
proliferation.
Figure 3 Late marginal zone lymphoma of MALT-type.
Mutations in the B-cells makes them independent of the
T-cell drive and of the presence of H. pylori. Some cases
progress to diffuse large B-cell lymphoma with aggregates
of immunoblasts outside germinal centres.